Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTPW) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to 531.42%.

  • 60 Degrees Pharmaceuticals' EBITDA Margin rose 10622200.0% to 531.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 833.96%, marking a year-over-year increase of 7714800.0%. This contributed to the annual value of 1309.43% for FY2024, which is 1702000.0% up from last year.
  • According to the latest figures from Q3 2025, 60 Degrees Pharmaceuticals' EBITDA Margin is 531.42%, which was up 10622200.0% from 1590.01% recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' EBITDA Margin peaked at 8190.47% during Q3 2023, and registered a low of 15148.79% during Q1 2023.
  • For the 4-year period, 60 Degrees Pharmaceuticals' EBITDA Margin averaged around 1730.91%, with its median value being 1369.44% (2025).
  • Over the last 5 years, 60 Degrees Pharmaceuticals' EBITDA Margin had its largest YoY gain of 155524700bps in 2024, and its largest YoY loss of -97841200bps in 2024.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' EBITDA Margin stood at 4451.68% in 2022, then plummeted by -136bps to 1585.0% in 2023, then soared by 46bps to 849.49% in 2024, then skyrocketed by 37bps to 531.42% in 2025.
  • Its EBITDA Margin was 531.42% in Q3 2025, compared to 1590.01% in Q2 2025 and 1153.89% in Q1 2025.